{
    "nct_id": "NCT06713564",
    "official_title": "A Phase 1b, Single Dose, Open-Label, Dose-escalation Study to Investigate the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer",
    "inclusion_criteria": "* ECOG performance status of 0 to 2\n* Have a primary diagnosis, or a high clinical suspicion, for cancer in the lung based on CT, biopsy, or other imaging.\n* Are scheduled to undergo surgical thoracoscopy and resection of the lung.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindications for surgery or any medical condition that in the opinion of the investigator could jeopardize the safety of the subject\n* No planned surgical use of any other fluorescent optical imaging agent, or exposure to another optical imaging agent within 8 weeks prior to surgery\n\nHistory of any drug-related hypersensitivity or anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study, or known shellfish allergies.\n\nKnown sensitivity to near infrared light\n\nPatients with impaired renal function as defined by a creatinine clearance (CrCl) <60 mL/min at Screening, according to the Cockcroft-Gault formula ((140 - age) × body weight/plasma creatinine × 72 (× 0.85 for female)\n\nHistory, or presence in the ECG at Screening, of any clinically significant abnormalities including cardiac conduction abnormalities such as Fridericia's corrected QTc interval (QTcF) > 470 ms",
    "miscellaneous_criteria": ""
}